Why Ligand Pharmaceuticals Incorporated (LGND) stock moved
Ligand Pharmaceuticals Incorporated (LGND) shares rose 1.3% to $284.10 as of September 1, 2026, a modest gain from the prior close of $280.49. BestStocks flagged the session as a major change for LGND. The move is tied to price move up. Below, we break down what changed for LGND, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
LGND climbed 1.3% to $284.10
Ligand Pharmaceuticals Incorporated (LGND) moved +2.65% from $276.77 to $284.10 on 2026-08-31. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average, indicating routine trading activity. LGND earnings are scheduled for 2026-11-05 with consensus EPS estimate of $2.62; results and forward guidance could provide directional catalysts.
What it means for Ligand Pharmaceuticals Incorporated investors
For Ligand Pharmaceuticals Incorporated investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Material positive event; Positive 1.3% session move. Weighing against that: Ligand Pharmaceuticals Incorporated (LGND) moved -3.69% from $304.37 to $293.15 on 2026-08-07; Ligand Pharmaceuticals Incorporated (LGND) moved -3.10% from $303.39 to $293.99 on 2026-07-20. Wall Street's consensus price target sits at $338.50, implying +19.1% upside from $284.10. BestStocks rates the overall signal quality weak (37/100). With earnings roughly 65 days out, the next report is the most likely near-term test of the move.
LGND price reaction
LGND last traded at $284.10, up $3.61 (+1.29%) from the previous close of $280.49. The session traded on 0.6× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $280.18 and $302.57, and it currently sits about 18% of the way up that band.
Bullish and bearish analyst opinions on Ligand Pharmaceuticals Incorporated (LGND)
The consensus analyst price target on Ligand Pharmaceuticals Incorporated (LGND) is $338.50, 19.1% above the recent $284.10. Over the past 90 days analysts logged 0 upgrades, 6 maintains, and 0 downgrades. Here is how the bullish and bearish cases on LGND line up.
The bullish case
- Wall Street's consensus price target of $338.50 implies +19.1% upside from $284.10.
- The Street's most bullish target is $358.00 (+26.0%).
- Material positive event.
- Positive 1.3% session move.
- Ligand Pharmaceuticals Incorporated (LGND) moved +3.90% from $293.99 to $305.47 on 2026-07-21.
The bearish case
- Ligand Pharmaceuticals Incorporated (LGND) moved -3.69% from $304.37 to $293.15 on 2026-08-07.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 1, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for LGND
Frequently asked questions about LGND
Why did Ligand Pharmaceuticals Incorporated (LGND) stock move?
LGND rose 1.3% to $284.10. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did LGND stock rise?
LGND gained 1.29% ($3.61) versus the prior close of $280.49, last trading at $284.10 on 0.6× average volume.
When is Ligand Pharmaceuticals Incorporated's next earnings date?
LGND's next earnings report is estimated for 2026-11-05 — about 65 days away.
What is the analyst price target for LGND?
The consensus analyst price target for LGND is $338.50, about 19.1% above the current $284.10. Over the past 90 days, analysts recorded 0 upgrades, 6 maintains, and 0 downgrades.
How BestStocks tracks LGND
This page is generated automatically by BestStocks' change-detection system after price move up was detected and verified against independent data sources. It draws on 20 tracked change events for LGND, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 1, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.